Literature DB >> 11197609

Idiopathic pulmonary fibrosis: molecular mechanisms and possible therapeutic strategies.

B van den Blink1, H M Jansen, M P Peppelenbosch.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating disease with an almost universally terminal outcome. In recent years much insight has been gained into the pathogenesis of IPF from both a bleomycin mice-model as well as ex vivo human tissue studies. Alveolar damage and inflammation of unknown etiology, eventually leading to interstitial fibrosis, characterize IPF. Apoptosis has emerged as an important factor in the pathogenesis of IPF. This review will outline the current understanding of the immunological and molecular mechanisms underlying IPF and discuss new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11197609

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  3 in total

1.  Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia.

Authors:  E S Choi; E M Pierce; C Jakubzick; K J Carpenter; S L Kunkel; H Evanoff; F J Martinez; K R Flaherty; B B Moore; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 2.  Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.

Authors:  Claudia Jakubzick; Steven L Kunkel; Raj K Puri; Cory M Hogaboam
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Effect of early treatment with transcutaneous electrical diaphragmatic stimulation (TEDS) on pulmonary inflammation induced by bleomycin.

Authors:  Laisa A Santos; Carlos A Silva; Maria L O Polacow
Journal:  Braz J Phys Ther       Date:  2013-11-14       Impact factor: 3.377

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.